Drivers of Polypharmacy | Negative Consequences Associated with Polypharmacy [13,14,15,16] |
---|---|
i. Indiscriminate use of clinical practice guidelines (CPGs) designed for the management of single diseases in elderly, multimorbid patients [17, 18]. | i. Adverse drug events (ADEs) ii. Adverse drug reactions (ADRs) iii. Drug-drug interactions iv. Drug-disease interactions v. Medications non-adherence vi. Medication errors vii. Use of potentially inappropriate medications (PIMs) viii. Renal failure ix. Urinary incontinence x. Falls and fractures xi. Functional decline, disability and frailty xii. Cognitive impairment and delirium xiii. Malnutrition xiv. Decreased quality of life xv. Nursing home/long-term care placement xvi. Hospitalizations xvii. Mortality |
ii. Protocol-driven medicine that recommends prescribing medications as the first line of treatment and “stepping up” drug regimens with higher doses and/or additional drugs if targets are not reached [17, 19, 20]. | |
iii. Performance standards and incentives that coerce clinicians to follow guidelines focused on starting medications [18, 19]. | |
iv. Research gaps that leaves many aspects of polypharmacy poorly understood [18, 19]. | |
v. Inadequate clinician training on the management of polypharmacy (including monitoring, detecting, preventing, and evaluating adverse outcomes associated with polypharmacy) [18, 19]. | |
vi. Fragmented healthcare systems that results in uncoordinated treatment by multiple prescribers [9, 19, 21]. | |
vii. Growth of the pharmaceutical industry leading to an ever-increasing availability of medications for a growing number of medical conditions [19]. | |
viii. Influence of the pharmaceutical industry on clinicians [19] and funding of clinical drug trials [22] and professional societies that publish CPGs [23]. |